Can Apple's new ResearchKit really transform drug R&D?

Amid all the pomp, circumstance and sans serif fonts in Apple's ($APPL) latest product launch, the company took a break from pumping expensive new gadgetry to unveil a piece of software with the potential to change the medical research landscape. Dubbed ResearchKit, Apple's new platform promises to transform the world's hundreds of millions of iPhones into handheld gatherers of clinical data, which some say will usher in a new era of biomedical science but could well amount to more questions than answers. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.